Published Year: 2025
AI in Antibody Discovery Market - A Global and Regional Analysis: Focus on Technology, Solution, App
The global AI in antibody discovery market is projected to reach $4,843.1 million by 2035 from...
Market Research Report
A quick peek into the report
Global Antibody Discovery Market: Industry Overview
The global antibody discovery market was valued at approximately $11.15 billion in 2025 and is projected to grow $35.35 billion by 2035, at a CAGR of around 12.23%. The global antibody discovery market is rapidly evolving, driven by advancements in engineering technologies, automation, and artificial intelligence. A major trend shaping this growth is the shift toward fully human and humanized antibodies, which improve therapeutic safety, specificity, and efficacy while reducing immunogenicity. Supported by technologies such as phage display, transgenic animal models, and glycoengineering, these formats are transforming treatments for cancer, autoimmune, and infectious diseases. Additionally, the integration of high-throughput screening, next-generation sequencing, and automation has streamlined antibody identification and optimization, significantly shortening development timelines and improving cost efficiency. The increasing reliance on contract research organizations further enhances scalability and accelerates innovation by providing specialized infrastructure and expertise in antibody screening and engineering.
Additionally, artificial intelligence and machine learning are reshaping the discovery process by enabling predictive modeling, affinity optimization, and rapid sequence design. These tools enhance precision and reduce development costs, supporting the growing demand for precision therapies. Innovations such as bispecific antibodies, antibody-drug conjugates, and single-domain antibodies are broadening therapeutic potential across oncology, immunology, and rare diseases. Despite challenges such as high production costs and competition from alternative modalities such as gene and cell therapies, continued progress in automation, bioinformatics, and process scalability positions the global antibody discovery market for sustained growth and technological maturity in the coming decade.
Global Antibody Discovery Market Lifecycle Stage
The global antibody discovery market is positioned in the growth stage of its lifecycle, characterized by accelerating innovation, expanding adoption across therapeutic areas, and intensifying competition among established companies and emerging players. The market has evolved beyond early-stage scientific exploration into a mature, technology-driven ecosystem where efficiency, automation, and precision increasingly define competitive advantage. This phase is marked by the rapid integration of artificial intelligence and machine learning-enabled discovery platforms, high-throughput screening, and multi-omics integration, which are significantly reducing development timelines and enhancing candidate success rates.
As the market continues to mature, focus is shifting from innovation-driven discovery toward process optimization, clinical validation, and cost efficiency. Competitive dynamics are expected to intensify as new entrants leverage computational biology and synthetic biology approaches to challenge traditional discovery models. Over the next decade, the global antibody discovery market is anticipated to progress toward the early maturity phase, characterized by broader clinical adoption, standardized workflows, and increasing regulatory clarity.
Figure: Global Antibody Discovery Market Snapshot
Market Segmentation:
Segmentation 1: By Offering
• Product
o Antibody Discovery Platforms & Systems
o Kits & Reagents
o Antibody Libraries
o Others
• Services
o Antigen Designing & Preparation
o Hit Generation & Screening
o Lead Selection & Optimization
o Antibody Engineering & Characterization
o Other Services
Products account for the larger share of the antibody discovery market as they include antibody discovery platforms and systems, kits, reagents, and antibody libraries, among others that are essential, high-value, and recurrently consumed across discovery workflows. While services generate significant revenue, product sales are often bundled into multiple projects, creating a broader revenue base.
Segmentation 2: By Technology
• Phage Display Technology
• Hybridoma Technology
• Single B-Cell Technologies
• Transgenic Animal-based Methods
• Other Technologies
Phage display technology accounts for the largest share in the antibody discovery market as it allows the screening of very large antibody libraries in vitro, making it highly efficient for isolating binders against diverse and difficult targets. Its ability to generate fully human antibodies without the need for immunization has made it the most widely used technology by pharmaceutical and biotechnology companies and other end users.
Segmentation 3: By Antibody Type
• Monoclonal Antibodies
• Polyclonal Antibodies
• Next-Generation Antibodies
o Bispecific Antibodies
o Antibody-Drug Conjugates
o Nanobodies
o Other Engineered Antibodies
Monoclonal antibodies account for the largest share of the global antibody discovery market as they are well-established, widely approved, and form the backbone of therapeutic pipelines across multiple disease areas. However, next-generation antibodies are expected to be the fastest growing segment, driven by the rapid development and clinical success of bispecifics, ADCs, and other engineered formats that offer improved efficacy and novel mechanisms of action.
Segmentation 4: By Nature
• Human Antibodies
• Humanized Antibodies
• Chimeric Antibodies
• Murine Antibodies
Human antibodies hold the largest share in the antibody discovery market as they offer the highest compatibility and lowest risk of immunogenicity in patients. Advances in transgenic animal models, phage display, and single B-cell technologies have enabled efficient generation of fully human antibodies, making them the preferred choice as a safe and long-lasting therapeutics.
Segmentation 5: By Therapeutic Area
• Oncological Disorders
• Immunological Disorders
• Infectious Diseases
• Cardiovascular Disorders
• Neurological Disorders
• Other Therapeutic Areas
Oncology disorders account for the largest share of the antibody discovery market because antibodies have become a cornerstone of cancer therapy, with numerous monoclonal antibodies, bispecifics, and ADCs approved and in late-stage pipelines. The high unmet need, significant R&D investment, and rapid adoption of next-generation antibody formats in immuno-oncology drive sustained dominance of this therapeutic area.
Segmentation 6: By End User
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Academic and Research Institutes
• Others
Based on end-user segmentation, pharmaceutical and biotechnology companies are expected to account for the largest share of the global antibody discovery market in 2024 as they conduct extensive in-house R&D and maintain proprietary discovery platforms to build differentiated pipelines. These companies also actively collaborate with others to accelerate antibody discovery, while leveraging licensing agreements and acquisitions to expand their therapeutic portfolios. Their strong financial capacity and emphasis on advancing next-generation antibody modalities further reinforce their leading role in this market.
Segmentation 7: By Region
• North America
• Europe
• Asia-Pacific
• Rest-of-the-World
North America is expected to hold the largest share of the global antibody discovery market, driven by the strong presence of major biopharmaceutical companies, advanced research infrastructure, and high R&D investments. The region benefits from early adoption of AI-driven discovery platforms, extensive clinical trial activity, and supportive regulatory frameworks that accelerate biologics development and commercialization.
Demand – Drivers and Limitations
Demand Drivers for the Global Antibody Discovery Market:
• Advancements in Antibody Engineering for Therapeutic Applications
• Increasing Prevalence of Chronic Diseases
Limitations for the Global Antibody Discovery Market:
• Rising Shift toward Alternative Antibody-Based Treatment Modalities
• High Costs Restrict Widespread Adoption of Antibody Therapies
Antibody Discovery Market - A Global and Regional Analysis
Focus on Offering, Technology, Antibody Type, Therapeutics, Nature, End User, and Country - Analysis and Forecast, 2025-2035
Some Faq's
Frequently Asked Questions
Antibody discovery is the process of identifying and developing antibodies that can specifically recognize and bind to target antigens for therapeutic or diagnostic use. It involves multiple stages, including target identification, antibody generation through technologies such as hybridoma, phage display, or transgenic animal models, screening for high-affinity candidates, and subsequent humanization or optimization for clinical application. The goal is to develop monoclonal, bispecific, or fully human antibodies that demonstrate high specificity, efficacy, and safety for diseases such as cancer, autoimmune disorders, and infectious diseases.
The growth of the global antibody discovery market is primarily driven by advancements in antibody engineering and the increasing prevalence of chronic diseases. Continuous innovation in antibody engineering, including the development of fully human and humanized antibodies, has significantly enhanced therapeutic specificity, reduced immunogenicity, and improved safety profiles. These antibodies supported by technologies such as phage display, transgenic models, and glycoengineering are increasingly used to develop next-generation treatments in oncology, autoimmune, and infectious diseases. Additionally, the rising burden of chronic conditions worldwide has intensified demand for targeted and personalized therapies, positioning antibody-based treatments as essential components of modern biopharmaceutical pipelines.
The global antibody discovery market faces challenges such as competition from alternative treatment modalities and high production costs. Emerging alternatives offer advantages such as lower immunogenicity, simpler manufacturing, and broader applicability, posing competitive pressure on antibody-based approaches. Furthermore, the complex and expensive production processes for monoclonal antibodies, involving high-cost bioreactors, raw materials, and regulatory compliance, limit accessibility, particularly in low- and middle-income countries. These challenges underscore the need for more scalable, cost-efficient, and innovative discovery and manufacturing approaches to ensure broader adoption and affordability.
This report offers a comprehensive, end-to-end analysis of the global antibody discovery market, combining market sizing, growth forecasts, competitive intelligence, and technology insights. It emphasizes emerging innovations, including AI integration. In addition, the report includes extensive company profiling, benchmarking, funding analysis, partnership tracking, patent analysis, equipping stakeholders with actionable insights for strategic decision-making. Its value lies in integrating technological developments with commercial and competitive intelligence, supporting informed choices regarding R&D prioritization, market entry, and partnership strategies.
This report is intended for biopharmaceutical companies, biotechnology firms, and research organizations involved in antibody development, therapeutic innovation, and biologics R&D. It will also benefit CROs, CDMOs, academic institutions, and technology providers specializing in antibody screening, engineering, and automation platforms. Furthermore, investors, venture capitalists, and strategic decision-makers can leverage the insights to identify growth opportunities, evaluate partnerships, and align investment priorities with emerging trends such as AI-driven antibody discovery, bispecific and fully human antibody development, and automation-driven pipeline acceleration.
Similar Product
You may also like